Skip to content

NRXP

NRX Pharmaceuticals, Inc.

NASDAQ · Healthcare · Biotechnology · US

$2.63
+1.15%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
+35.3%
EBIT
-40.3%
EPS
+68.1%
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
+2967.8%
EBITDA
+5.4%
EPS
+18.6%

Three-year CAGR

Revenue
—
EBITDA
-15.7%
EBIT
+17.7%
Net income
-13.9%
EPS
+43.9%
Free cash flow
-32.7%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026